| Description | Fosdevirine (GSK2248761) is a selective and potent non-nucleoside reverse transcriptase (NNRTI) inhibitor with anti-HIV activity for the study of neurological related disorders such as late-onset epilepsy. |
| In vitro | Fosdevirine demonstrates potent in vitro antiviral efficacy against single-point mutations K103N and Y181C, and is similarly effective against the majority of double mutants[1]. |
| Synonyms | GSK-2248761A, IDX 899, GSK 2248761A, GSK 2248761, GSK-2248761, IDX-12899, GSK2248761, FDV, GSK2248761A |
| molecular weight | 413.79 |
| Molecular formula | C20H17ClN3O3P |
| CAS | 1018450-26-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Castellino S, et al. Central nervous system disposition and metabolism of Fosdevirine (GSK2248761), a non-nucleoside reverse transcriptase inhibitor: an LC-MS and Matrix-assisted laser desorption/ionization imaging MS investigation into central nervous system toxicity. Chem Res Toxicol. 2013 Feb 18;26(2):241-51. 2. Margolis DA, Eron JJ, DeJesus E, White S, Wannamaker P, Stancil B, Johnson M. Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761). Antivir Ther. 2014;19(1):69-78. doi: 10.3851/IMP2689. Epub 2013 Oct 24. PubMed PMID: 24158593. 3. Ölgen S. Recent development of new substituted indole and azaindole derivatives as anti-HIV agents. Mini Rev Med Chem. 2013 Oct;13(12):1700-8. Review. PubMed PMID: 23895189. |